Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-sense tolerogenic dendritic cell safety study in type 1 diabetes
NL-OMON21892Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- May 2015
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of proinsulin peptide-loaded tolerogenic dendritic cells in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Primary safety endpoints and Primary feasibility endpoints. Started May 2015; status: recruiting.
02
Drugs
proinsulin peptide-loaded tolerogenic dendritic cells
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON21892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21892.